(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
-2.35% £ 2.08
Live Chart Being Loaded With Signals
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives...
Stats | |
---|---|
Объем за сегодня | 936 693 |
Средний объем | 1.52M |
Рыночная капитализация | 8.66M |
EPS | £-0.00250 ( Q2 | 2023-06-30 ) |
Дата следующего отчета о доходах | ( £0 ) 2024-08-28 |
Last Dividend | £1.000 ( 2021-12-14 ) |
Next Dividend | £0 ( N/A ) |
P/E |
-2.08 (Sector) 0 (Industry) 0 |
ATR14 | £0.0550 (2.68%) |
ImmuPharma PLC Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
ImmuPharma PLC Финансовые показатели
Annual | 2023 |
Выручка: | £0 |
Валовая прибыль: | £-37 607.00 (0.00 %) |
EPS: | £-0.00810 |
FY | 2023 |
Выручка: | £0 |
Валовая прибыль: | £-37 607.00 (0.00 %) |
EPS: | £-0.00810 |
FY | 2022 |
Выручка: | £0 |
Валовая прибыль: | £-117 563 (0.00 %) |
EPS: | £-0.0126 |
FY | 2021 |
Выручка: | £118 350 |
Валовая прибыль: | £0.00 (0.00 %) |
EPS: | £-0.0325 |
Financial Reports:
No articles found.
ImmuPharma PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
First Dividend | £1.000 | 2021-12-14 |
Last Dividend | £1.000 | 2021-12-14 |
Next Dividend | £0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | £1.000 | -- |
Avg. Dividend % Per Year | 0.80% | -- |
Score | 0.33 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2021 | £1.000 | 8.00% |
2022 | £0 | 0.00% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
14 Dec 2021 | £1.000 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
DNA2.L | Dividend Royal | 2024-04-18 | Quarterly | 9 | 16.51% | 8.69 |
FAIR.L | Dividend Royal | 2024-05-30 | Quarterly | 9 | 10.77% | 8.67 |
MPLS.L | Dividend Royal | 2024-04-11 | Quarterly | 7 | 12.84% | 8.67 |
BGLF.L | Dividend Royal | 2024-05-02 | Quarterly | 9 | 10.03% | 8.50 |
SEPL.L | Dividend Royal | 2024-05-30 | Quarterly | 11 | 10.34% | 8.34 |
DNA3.L | Dividend Royal | 2024-04-18 | Quarterly | 12 | 14.16% | 8.31 |
DEC.L | Dividend Royal | 2024-08-29 | Quarterly | 8 | 59.83% | 7.91 |
AA4.L | Dividend Royal | 2024-04-11 | Quarterly | 9 | 12.37% | 7.88 |
IMB.L | Dividend Royal | 2024-08-22 | Quarterly | 28 | 7.10% | 7.51 |
FBH.L | Dividend Royal | 2024-05-02 | Annually | 22 | 11.26% | 7.46 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -32.54 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.255 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -1.936 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.807 | 0.800 | -0.967 | -0.773 | [1 - 3] |
quickRatioTTM | 0.125 | 0.800 | -3.97 | -3.18 | [0.8 - 2.5] |
cashRatioTTM | 0.125 | 1.500 | -0.416 | -0.623 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -2.58 | 1.000 | -2.07 | -2.07 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.00502 | 2.00 | -0.00167 | -0.00334 | [0 - 30] |
freeCashFlowPerShareTTM | -0.00533 | 2.00 | -0.00267 | -0.00533 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | -0.326 | 1.000 | -8.76 | -8.76 | [0.2 - 0.8] |
operatingProfitMarginTTM | -31.51 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.0386 | 0.800 | -3.08 | -2.46 | [0.5 - 2] |
Total Score | -6.30 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -2.08 | 1.000 | -0.311 | 0 | [1 - 100] |
returnOnEquityTTM | -1.936 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.00533 | 2.00 | -0.00178 | -0.00533 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.00502 | 2.00 | -0.00167 | -0.00334 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.842 | 1.500 | -8.95 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -15.93 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -3.03 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа